Tzitzi Evanthia, Pyrpasopoulou Athina, Kalmoukos Panagiotis, Kefas Aristeidis, Kyrana Zacharenia, Doukelis Panagiotis, Varouktsi Anna, Imprialos Kostas, Doumas Michail
COVID Department, Hippokration Hospital Thessaloniki, Thessaloniki, Greece.
Monoclon Antib Immunodiagn Immunother. 2023 Feb;42(1):48-50. doi: 10.1089/mab.2022.0033. Epub 2023 Feb 9.
Monoclonal antibodies targeted against SARS-COV-2 have been recruited in the challenging treatment of COVID-19 with few clinically significant side effects. Casivirimab/imdevimab, a combination of monoclonal antibodies targeted against SARS-COV-2 spike protein, was shown to effectively prevent recently infected high-risk COVID-19 patients from developing severe disease. Its efficacy waned with the emergence of the resistant omicron variant in late 2021. We recorded the real-world effect of casivirimab/imdevimab on 116 high-risk COVID-19 patients. Cumulative need for hospitalization, mortality, new-onset disease, and reinfections was monitored. Casivirimab/imdevimab effect was independent from previous immunization. The cohort was further divided into two subgroups: patients infected during a delta variant prevalent period were more likely to become admitted but as likely to die than patients infected with the omicron variant, in support of its protective effect from clinical studies. Cumulative reinfection incidence in treated patients, interestingly, was lower than in the general population.
靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的单克隆抗体已被用于新冠肺炎的挑战性治疗，且几乎没有具有临床意义的副作用。卡西瑞单抗/依米德维单抗是一种靶向SARS-CoV-2刺突蛋白的单克隆抗体组合，已被证明能有效预防近期感染的高危新冠肺炎患者发展为重症疾病。随着2021年末耐药的奥密克戎变异株出现，其疗效逐渐减弱。我们记录了卡西瑞单抗/依米德维单抗对116例高危新冠肺炎患者的实际治疗效果。监测了住院累计需求、死亡率、新发疾病和再次感染情况。卡西瑞单抗/依米德维单抗的治疗效果与既往免疫接种无关。该队列进一步分为两个亚组：在德尔塔变异株流行期间感染的患者比感染奥密克戎变异株的患者更易入院，但死亡可能性相同，这支持了临床研究中其具有保护作用的结论。有趣的是，接受治疗患者的累计再次感染发生率低于普通人群。
